These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 2411125)

  • 21. Serum pancreatic enzyme assays in acute abdomen: a comparative prospective study.
    Ventrucci M; Pezzilli R; Montone L; Plate L; Buonamici L; Bergami R; Conci T
    Ital J Gastroenterol; 1992; 24(3):115-8. PubMed ID: 1373336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum levels of the carbohydrate antigen CA-50 in pancreatic disease.
    Blind PJ; Dahlgren ST
    Acta Chir Scand; 1987 Jan; 153(1):45-9. PubMed ID: 3472420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical evaluation of the tumor marker CA 19-9 in comparison with carcinoembryonic antigen (CEA) in surgical pre- and postoperative diagnosis].
    Lorenz M; Happ J; Hottenrott C; Maul FD; Baum RP; Hör G; Encke A
    Nuklearmedizin; 1986 Feb; 25(1):9-14. PubMed ID: 3459133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of different tumor markers in the early diagnosis and prognosis of pancreatic carcinoma and chronic pancreatitis.
    Hámori J; Arkosy P; Lenkey A; Sápy P
    Acta Chir Hung; 1997; 36(1-4):125-7. PubMed ID: 9408313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Evaluation of pancreatic oncofetal antigen (POA) in the diagnosis of pancreatic cancer].
    Nishida K
    Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt 2):601-8. PubMed ID: 6349542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum markers and clinical data in diagnosing pancreatic cancer: a contrastive approach.
    Fabris C; Del Favero G; Basso D; Piccoli A; Meggiato T; Angonese C; Plebani M; Leandro G; Burlina A; Naccarato R
    Am J Gastroenterol; 1988 May; 83(5):549-53. PubMed ID: 3163228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Values of carcinoembryonic antigen, elastase 1, and carbohydrate antigen determinant in aspirated pancreatic cystic fluid in the diagnosis of cysts of the pancreas.
    Tatsuta M; Iishi H; Ichii M; Noguchi S; Yamamoto R; Yamamura H; Okuda S
    Cancer; 1986 May; 57(9):1836-9. PubMed ID: 2420441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Diagnostic value of CA 19-9 and CEA in gastrointestinal pathology].
    Patai A; Héber S; Döbrönte Z; Kovács LG
    Orv Hetil; 1992 May; 133(21):1301-4, 1307. PubMed ID: 1603581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma.
    Nazli O; Bozdag AD; Tansug T; Kir R; Kaymak E
    Hepatogastroenterology; 2000; 47(36):1750-2. PubMed ID: 11149048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A clinical evaluation of carbohydrate antigen 19-9 and carcinoembryonic antigen in patients with pancreatic carcinoma.
    Satake K; Kanazawa G; Kho I; Chung YS; Umeyama K
    J Surg Oncol; 1985 May; 29(1):15-21. PubMed ID: 3857396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparison of the tumor markers CEA and CA 19-9 in colorectal diagnosis].
    Heptner G; Domschke S; Krapf F; Schneider MU; Iro H; Domschke W
    Dtsch Med Wochenschr; 1984 Aug; 109(35):1309-12. PubMed ID: 6590287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
    Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
    Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of local and systemic factors in increasing serum glycoprotein markers of pancreatic cancer.
    Fabris C; Basso D; Piccoli A; Meggiato T; Del Favero G; Fogar P; Panozzo MP; Faggian D; Vianello D; Plebani M
    J Med; 1991; 22(3):145-56. PubMed ID: 1770322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumour markers in pancreatic cancer.
    Haglund C; Kuusela P; Roberts PJ
    Ann Chir Gynaecol; 1989; 78(1):41-53. PubMed ID: 2667448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective study.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Anticancer Res; 1992; 12(5):1687-93. PubMed ID: 1332581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor markers carbohydrate antigens CA 19-9 and CA-50 and carcinoembryonic antigen in pancreatic cancer and benign diseases of the pancreatobiliary tract.
    Harmenberg U; Wahren B; Wiechel KL
    Cancer Res; 1988 Apr; 48(7):1985-8. PubMed ID: 3349472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of a new immunoassay for determining serum pancreatic isoamylase with two standard techniques.
    Ventrucci M; Pezzilli R; Gullo L
    Am J Gastroenterol; 1990 Oct; 85(10):1381-5. PubMed ID: 2220732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Carbohydrate antigen CA 19-9: value in pancreatic pathology].
    Venot J; Vincent D; Gainant A; Descottes B; Cessot F; Beck C
    Gastroenterol Clin Biol; 1986 Mar; 10(3):208-10. PubMed ID: 3460925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.
    Liao Q; Zhao YP; Yang YC; Li LJ; Long X; Han SM
    Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):641-5. PubMed ID: 18086633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.